Radiation Res & Translational Biology

$268,331P30FY2013CANIH

Thomas Jefferson University, Philadelphia PA

Investigators

Linked publications & trials

Paper 39763727 Paper 39580581 Paper 39565860 Paper 39461996 Paper 39420298 Paper 39386511 Paper 39315411 Paper 39266679 Paper 39253495 Paper 39108244 Paper 39105261 Paper 39079076 Paper 39044358 Paper 38926911 Paper 38893249 Paper 38876912 Paper 38785202 Paper 38766099 Paper 38739450 Paper 38738619 Paper 38703693 Paper 38507713 Paper 38503750 Paper 38462666 Paper 38452174 Paper 38390323 Paper 38384841 Paper 38265919 Paper 38198557 Paper 38182585 Paper 38177911 Paper 38152610 Paper 38064712 Paper 38034400 Paper 38014626 Paper 38003928 Paper 37963876 Paper 37958304 Paper 37956856 Paper 37952769 Paper 37923138 Paper 37874216 Paper 37847239 Paper 37690972 Paper 37633778 Paper 37558133 Paper 37555986 Paper 37549289 Paper 37546718 Paper 37536941 Paper 37497753 Paper 37422479 Paper 37392563 Paper 37377895 Paper 37343247 Paper 37331825 Paper 37244749 Paper 37174743 Paper 37155893 Paper 37071027 Paper 36989737 Paper 36795988 Paper 36778385 Paper 36734633 Paper 36708948 Paper 36651749 Paper 36624251 Paper 36598655 Paper 36561929 Paper 36497250 Paper 36480484 Paper 36473135 Paper 36417857 Paper 36321991 Paper 36253248 Paper 36229842 Paper 36223548 Paper 36198166 Paper 36154696 Paper 36152632 Paper 36054264 Paper 36037225 Paper 36032972 Paper 36031853 Paper 36030052 Paper 36007626 Paper 35995140 Paper 35954437 Paper 35943291 Paper 35863824 Paper 35779741 Paper 35767952 Paper 35741402 Paper 35732075 Paper 35727609 Paper 35695878 Paper 35674408 Paper 35666082 Paper 35657206 Paper 35474308

Abstract

PROJECT SUMMARY (See instructions); The Radiation Research and Translational Biology, (RRTB) program goal is to improve combination radiation therapies by 1) designing and testing new molecular targets identified by mechanistic studies, and 2) addressing tumor resistance to therapy and bypass of immune surveillance, and 3) designing, assessing and improving technologies that diagnose, stage, and deliver therapies for cancer patients. Program members address these goals with multidisciplinary efforts in biochemistry, immunology, drug design, preclinical models, and clinical experience, to accelerate translation from bench to bedside. The Program has been strengthened by integration of members from the former Program in Cancer Immunology. The current RRTB program, comprised of 34 basic, translational and clinical investigators from eleven departments, thus combines basic and clinical research strengths to conduct bench to bedside research and can reverse translate clinical data to inform further translational innovations. This work is supported by 36 peer-reviewed grants totaling direct funds of $13.2 million ($5.3 million from NCI). The total number of publications generated by Program members from 2007 to 2012 is 543 of which 11% are Intra-programmmatic and 22% are Inter-programmatic, with 4.6% being both. The specific research themes ofthe RRTB Program are: (1) Improve RT therapies by defining and characterizing molecular targets for ionizing radiation and for combined therapies, vaccine development and BMT (2) Immune tolerance and strategies for immune surveillance. (3) Tumor resistance: Microenvironment, hypoxia and angiogenesis. (4) Protecting normal tissues: normal tissue injury/genotoxic stress. (5) Clinical translation of diagnostic and therapeutic innovations, and (6) Improving clinical practice: Biomedical/Bioinformatics and Comparitive Effectiveness Research (CER). This program will continually generate new collaborations, intra- and interprogrammatically, and fresh research directions with other research programs in the cancer center.

View original record on NIH RePORTER →